Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on
the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with …

… Dr Hirsch and Ms Martinez Chanza contributed equally to this work. … Conflict of Interest
Disclosures: Ms Martinez Chanza reports support for research travel from Pfizer and Ipsen, and …

Importance DNA repair gene aberrations occur in 20% to 30% of patients with castration-resistant
prostate cancer (CRPC), and some of these aberrations have been associated with …

Immune checkpoint inhibitors (ICIs) are soluble antibodies that have dramatically changed
the outcomes including overall survival in a subset of kidney tumors, specifically in renal cell …

Background Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse
events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment …

Background MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive
subgroup of renal cell carcinoma harboring high expression of c-MET. While TRCC response …

Purpose To date, there has not been a large, systematic evaluation of the prevalence of
germline risk variants in urothelial carcinoma (UC). Methods We evaluated the frequency of …

We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen (PSMA)
for response assessment in metastatic prostate cancer (PCa) patients treated with taxane…

Objective To investigate the association between Prostate-Specific Membrane Antigen (PSMA)
expression changes on positron emission tomography–computed tomography (PET/CT) …

Background Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year
overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have …